Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
Potential Lenacapavir Supply, 2026-28
Source of Lenacapavir for PrEP Supply to Early Adopter Countries
The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery starting in early 2026.
HIV Vaccine Clinical Trials Pipeline
This graphic summarizes the state of HIV vaccine research, detailing the different immunological approaches in clinical trials, the specific candidates being studied, and the collaborative networks of funders and developers working toward an effective vaccine.
AVAC Comment Submission on the White House OMB Proposed Federal Financial Assistance Rule
HIV Prevention Product Overview
The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.
What Does It Take to Conduct HIV Cure Research?
Progress towards an HIV cure depends on strengthening four critical systems: lab equipment, sustainable funding, policy & programs, and training.
Long-Acting HIV Treatment Pipeline
AVAC has begun to track the research pipeline for long-acting HIV treatment (LA-ART). A rapidly expanding pipeline for LA-ART has the potential to introduce new regimens with dosing frequencies that range from weeks to months to, eventually, years. The benefits of LA-ART include reduced drug dosing, frequency, and number of drugs, with the potential for associated decreases in the cost of medications and the burden on health systems. New drug classes could close treatment gaps in children, adolescents, and those with high viremia, comorbidities and resistance. Ongoing clinical research will hopefully further demonstrate whether there are trade-offs (treatment failures or resistance) between LA-ART and highly effective daily oral ART. In addition to the new long-acting products, simplified single-tablet daily regimens are also in development.
Speeding Up Access to PrEP
Time from efficacy results to key milestones
The timeline for hitting key milestones in product introduction is moving faster for injectable LEN than for any previous PrEP products, starting from the announcement of efficacy results in Phase III trials. LEN’s accelerated timeline compared to oral PrEP, DVR, and CAB reflects a field-wide effort to learn lessons from previous PrEP rollout and not repeat the mistakes of the past.
Advocates’ Primer: Understanding Bioequivalence and Pharmacokinetic Studies in Next-Generation HIV Prevention Products
As more next-generation PrEP options become available, HIV prevention research is shifting away from large, multi-year efficacy trials toward pharmacokinetic (PK) and bioequivalence (BE) studies — which test whether a new formulation behaves in the body like a product already proven to work. This primer explains the shift and what it means for advocates.
An Advocates’ Checklist for Lenacapavir for PrEP Introduction
The Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting HIV PrEP developed a new resource that offers practical guidance to help civil society, advocates and implementers accelerate equitable access to LEN for PrEP. The checklist is designed to support faster, community-centered rollout ahead of broader generic availability in 2027.